Unadjusted change in PT and PTT 1 hour after first transfusion
. | Mean before transfusion ± SD, s (min, max) . | Mean after transfusion ± SD, s (min, max) . | Mean unadjusted change ± SD, s (min, max) . | P* . | Treatment difference of means . | 95% CI† . |
|---|---|---|---|---|---|---|
| Efficacy-evaluable population | ||||||
| PT | ||||||
| Test; n = 58 | 22.3 ± 10.6 (10.5, 83.9) | 18.8 ± 4.5 (12.2, 32.6) | 3.5 ± 9.3 (–5.2, 65.3) | .002 | –0.2 | –3.0, 2.5 |
| Control; n = 58 | 21.9 ± 6.5 (11.4, 40.8) | 18.2 ± 3.5 (11.4, 26.0) | 3.7 ± 5.4 (–6.1, 18.6) | — | — | — |
| PTT | ||||||
| Test; n = 56 | 42.5 ± 13.4 (25.3, 99.2) | 39.3 ± 11.2 (26.3, 96.8) | 3.1 ± 11.0 (–34.6, 45.3) | .348 | 1.3 | –6.0, 8.6 |
| Control; n = 55 | 43.6 ± 16.8 (27.5, 133.1) | 41.4 ± 23.0 (23.6, 200.0) | 1.8 ± 25.5 (–157.4, 66.3) | — | — | — |
| OLT population | ||||||
| PT | ||||||
| Test; n = 22 | 19.4 ± 7.2 (10.5, 40.9) | 17.7 ± 5.5 (12.2, 32.6) | 1.7 ± 5.7 (–5.2, 19.6) | .103 | –1.7 | –5.2, 1.8 |
| Control; n = 26 | 19.9 ± 7.2 (11.4, 40.8) | 16.5 ± 3.3 (11.4, 23.3) | 3.4 ± 6.6 (–6.1, 18.6) | — | — | — |
| PTT | ||||||
| Test; n = 22 | 39.1 ± 12.4 (25.6, 76.4) | 37.9 ± 14.2 (27.4, 96.8) | 1.2 ± 15.1 (–34.6, 45.3) | .890 | –4.1 | –13.5, 5.2 |
| Control; n = 25 | 42.7 ± 21.2 (28.2, 133.1) | 36.9 ± 8.7 (23.6, 66.8) | 5.3 ± 17.5 (–17.6, 66.3) | — | — | — |
| Non-OLT population | ||||||
| PT | ||||||
| Test; n = 36 | 24.0 ± 12.0 (15.9, 83.9) | 19.5 ± 3.7 (15.1, 28.3) | 4.5 ± 10.9 (–0.9, 65.3) | .042 | 0.6 | –3.2, 4.5 |
| Control; n = 32 | 23.6 ± 5.5 (14.9, 34.1) | 19.6 ± 3.0 (12.4, 26.0) | 3.9 ± 4.2 (–3.0, 17.3) | — | — | — |
| PTT | ||||||
| Test; n = 34 | 44.6 ± 13.7 (25.3, 99.2) | 40.2 ± 8.9 (26.3, 72.7) | 4.3 ± 7.4 (–5.1, 26.5) | .907 | 5.5 | –5.7, 16.7 |
| Control; n = 30 | 44.4 ± 12.6 (27.5, 94.7) | 45.3 ± 29.8 (27.0, 200) | –1.2 ± 30.6 (–157.4, 36.7) | — | — | — |
. | Mean before transfusion ± SD, s (min, max) . | Mean after transfusion ± SD, s (min, max) . | Mean unadjusted change ± SD, s (min, max) . | P* . | Treatment difference of means . | 95% CI† . |
|---|---|---|---|---|---|---|
| Efficacy-evaluable population | ||||||
| PT | ||||||
| Test; n = 58 | 22.3 ± 10.6 (10.5, 83.9) | 18.8 ± 4.5 (12.2, 32.6) | 3.5 ± 9.3 (–5.2, 65.3) | .002 | –0.2 | –3.0, 2.5 |
| Control; n = 58 | 21.9 ± 6.5 (11.4, 40.8) | 18.2 ± 3.5 (11.4, 26.0) | 3.7 ± 5.4 (–6.1, 18.6) | — | — | — |
| PTT | ||||||
| Test; n = 56 | 42.5 ± 13.4 (25.3, 99.2) | 39.3 ± 11.2 (26.3, 96.8) | 3.1 ± 11.0 (–34.6, 45.3) | .348 | 1.3 | –6.0, 8.6 |
| Control; n = 55 | 43.6 ± 16.8 (27.5, 133.1) | 41.4 ± 23.0 (23.6, 200.0) | 1.8 ± 25.5 (–157.4, 66.3) | — | — | — |
| OLT population | ||||||
| PT | ||||||
| Test; n = 22 | 19.4 ± 7.2 (10.5, 40.9) | 17.7 ± 5.5 (12.2, 32.6) | 1.7 ± 5.7 (–5.2, 19.6) | .103 | –1.7 | –5.2, 1.8 |
| Control; n = 26 | 19.9 ± 7.2 (11.4, 40.8) | 16.5 ± 3.3 (11.4, 23.3) | 3.4 ± 6.6 (–6.1, 18.6) | — | — | — |
| PTT | ||||||
| Test; n = 22 | 39.1 ± 12.4 (25.6, 76.4) | 37.9 ± 14.2 (27.4, 96.8) | 1.2 ± 15.1 (–34.6, 45.3) | .890 | –4.1 | –13.5, 5.2 |
| Control; n = 25 | 42.7 ± 21.2 (28.2, 133.1) | 36.9 ± 8.7 (23.6, 66.8) | 5.3 ± 17.5 (–17.6, 66.3) | — | — | — |
| Non-OLT population | ||||||
| PT | ||||||
| Test; n = 36 | 24.0 ± 12.0 (15.9, 83.9) | 19.5 ± 3.7 (15.1, 28.3) | 4.5 ± 10.9 (–0.9, 65.3) | .042 | 0.6 | –3.2, 4.5 |
| Control; n = 32 | 23.6 ± 5.5 (14.9, 34.1) | 19.6 ± 3.0 (12.4, 26.0) | 3.9 ± 4.2 (–3.0, 17.3) | — | — | — |
| PTT | ||||||
| Test; n = 34 | 44.6 ± 13.7 (25.3, 99.2) | 40.2 ± 8.9 (26.3, 72.7) | 4.3 ± 7.4 (–5.1, 26.5) | .907 | 5.5 | –5.7, 16.7 |
| Control; n = 30 | 44.4 ± 12.6 (27.5, 94.7) | 45.3 ± 29.8 (27.0, 200) | –1.2 ± 30.6 (–157.4, 36.7) | — | — | — |